← Eichor
Condition: Tremelimumab Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Tremelimumab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepato
Phase 2 · 4 location(s) · Riboscience, LLC. · NCT07175441A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immu
Phase 2 · 11 location(s) · Canadian Cancer Trials Group · NCT03847649Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Phase 2 · 3 location(s) · Anwaar Saeed · NCT06698250Durvalumab and Tremelimumab in Resectable HCC
Phase 2 · 3 location(s) · University Health Network, Toronto · NCT05440864Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
Phase 2 · 7 location(s) · Centre Leon Berard · NCT02029001Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Phase 1/Phase 2 · 1 location(s) · Yoon Jun Kim · NCT06911255Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
Phase 2/Phase 3 · 11 location(s) · UNICANCER · NCT06904170Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Phase 2 · 4 location(s) · Emory University · NCT07174570Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
Phase 2 · 6 location(s) · National Cancer Institute, Naples · NCT06341764TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
Phase 2 · 2 location(s) · The University of Hong Kong · NCT04988945Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular
Phase 2 · 3 location(s) · Enrico De Toni · NCT05844046STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
Phase 2 · 12 location(s) · Canadian Cancer Trials Group · NCT06880523Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Mary Feng, MD · NCT04430452Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du
NA · 10 location(s) · Centre Hospitalier Universitaire de Besancon · NCT06796114Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Phase 2 · 1 location(s) · Chang Gung Memorial Hospital · NCT06999707Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Ch
Phase 1 · 1 location(s) · Mayo Clinic · NCT06058663NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
Phase N/A · 29 location(s) · AstraZeneca · NCT06494540Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of
Phase 3 · 220 location(s) · AstraZeneca · NCT06921785Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointes
Phase 1/Phase 2 · 2 location(s) · Anwaar Saeed · NCT03539822Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in S
Phase 3 · 1 location(s) · Maximilian Diehn · NCT04585490Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Phase 2 · 1 location(s) · Chang Gung Memorial Hospital · NCT06999694Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabili
Phase 2 · 1 location(s) · AHS Cancer Control Alberta · NCT05451043Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metas
Phase 2 · 30 location(s) · National Cancer Institute (NCI) · NCT03606967MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life
Phase N/A · 24 location(s) · AstraZeneca · NCT07607769Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhos
Phase 2 · 1 location(s) · The University of Texas Health Science Center at San Antonio · NCT06526104Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma
Phase N/A · 24 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06806579Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cance
Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06564623Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Phase 1/Phase 2 · 2 location(s) · Baylor College of Medicine · NCT05932199SIRT With Tremelimumab and Durvalumab for Resectable HCC
Phase 1 · 3 location(s) · Jiping Wang, MD, PhD · NCT05701488Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Phase 2 · 4 location(s) · Georgetown University · NCT04499053
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.